Hépatite D:oubliée mais pas disparue
|Published in||Revue médicale suisse. 2010, vol. 6, no. 261, p. 1656-1659|
|Abstract||Hepatitis D virus (HDV) is a subviral agent which depends on the envelope proteins (HBsAg) of hepatitis B virus (HBV). Therefore, hepatitis D is observed only in patients infected with HBV. Chronic hepatitis D is the least frequent albeit most severe form of chronic viral hepatitis. A resurgence of chronic hepatitis D has been observed in Northern and Central Europe, mainly due to immigration of patients from regions with high prevalence. Every HBsAg-positive patient should be screened for concurrent HDV infection. Standard treatment consists of pegylated interferon-alpha for at least one year. Sustained virological response rates are approximately 20%. Liver transplantation should be considered in patients with advanced cirrhosis or limited hepatocellular carcinoma. Preventive measures for hepatitis D are the same as for hepatitis B.|
|Keywords||Antiviral Agents/therapeutic use — European Union/statistics & numerical data — Hepatitis B/complications — *Hepatitis D/diagnosis/epidemiology/therapy — Hepatitis D, Chronic — Hepatitis Delta Virus/isolation & purification — Humans — Interferon-alpha/therapeutic use — Liver Transplantation — Polyethylene Glycols/therapeutic use — Prevalence — Recombinant Proteins — World Health|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Etudes et traitement de l'hépatite C et B (554)|
|MORADPOUR, Darius, NEGRO, Francesco. Hépatite D:oubliée mais pas disparue. In: Revue médicale suisse, 2010, vol. 6, n° 261, p. 1656-1659. https://archive-ouverte.unige.ch/unige:20528|